Artelo Biosciences ARTL 深 滬
等待開盤 09-17 09:30:00 美东时间
3.75
-1.590
-29.78%
華盛通- 最 高4.90
- 今 開4.90
- 成交量 27.80万股
- 最 低 3.45
- 昨 收 5.34
- 總市值 205.42万
- 52周最高 179.1891
- 市盈率 靜 --
- 換手率 50.74%
- 52周最低 3.45
- 委 比 38.32%
- 總股本 54.78万
- 歷史最高 12150.00
- 量 比 5.33
- 振 幅 27.15%
- 歷史最低 3.45
- 每 手 1
- 風險率 37.41%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Artelo Biosciences shares are trading lower. The company reported nonclinical results showing its oral cannabinoid agonist ART27.13 cut body weight by about 20% in obese mice, matching semaglutide.
Artelo Biosciences shares are trading lower. The company reported nonclinical results showing its oral cannabinoid agonist ART27.13 cut body weight by about 20% in obese mice, matching semaglutide.
09-16 22:58
Artelo Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Artelo Biosciences, Inc. (Nasdaq: ARTL) announced that CEO Gregory D. Gorgas will participate in the H.C. Wainwright 28th Annual Global Investment Conference on September 14-16, 2026, in New York City. The company’s presentation will be available on September 11, 2026, at 7:00 a.m. ET, and can be accessed via the provided link. Management will also engage in one-on-one meetings with investors during the conference. Artelo focuses on developing th...
09-08 13:00
Artelo Biosciences Announces 1-For-9 Reverse Stock Split, Effective August 31
Artelo Biosciences, Inc. (NASDAQ:ARTL) ("Artelo" or the "Company"), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, today announced a 1-for-9 reverse stock sp...
08-27 20:03
Artelo Biosciences Announces Reverse Stock Split
Artelo Biosciences, Inc. announced a 1-for-9 reverse stock split to increase share price and improve marketability. The split will take effect on August 31, 2026, with the new CUSIP number 04301G805. Shareholders' ownership percentages remain unchanged, and fractional shares will be rounded up. Approximately 547,774 shares will be outstanding post-split. For details, review the Form 8-K filed August 27, 2026.
08-27 12:00
Artelo Biosciences Says USPTO Issues Notice Of Allowance For U.S. Patent Application Covering Intended Commercial Formulation Of ART27.13, Peripherally Selective Cannabinoid Agonist Currently In Phase 2 Studies
The Patent Claims are for the Intended Commercial Formulation of ART27.13 Expected to Extend Patent Protection for ART27.13 through 2041 SOLANA BEACH, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipi...
08-17 20:56
Artelo Biosciences Q2 EPS $(0.89) Up From $(16.83) YoY
Artelo Biosciences (NASDAQ:ARTL) reported quarterly losses of $(0.89) per share. This is a 94.71 percent increase over losses of $(16.83) per share from the same period last year.
08-13 20:21
Artelo Biosciences Says First Patient Dosed In DREAM Study Evaluating Effects Of ART27.13 In Patients With Glaucoma Or Ocular Hypertension; Initial DREAM Study Results Anticipated In Q4
Investigator-led study funded by Glaucoma UK and the HSC R&D Division expands ART27.13’s clinical potential into ophthalmology Initial DREAM Study Results Anticipated in Q4 2026 SOLANA BEACH, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmace...
08-10 20:49
Artelo Biosciences Announces Publication Of Article 'Evaluating The Pharmacokinetics, Efficacy, And Safety Of Low Dose Cannabidiol' In The British Journal Of Clinical Pharmacology
The peer-reviewed evaluation analyzed the efficacy, pharmacokinetics, and safety data obtained from over 50 studies using low-dose cannabidiol (CBD) commonly found in over-the-counter products — and exposes critical limitations and risks of these non-prescription CBD preparations at the doses admini...
07-22 20:41
Artelo Biosciences Announces Positive Results with ART27.13 in a Nonclinical Model of Paclitaxel-Induced Peripheral Neuropathy
Artelo Biosciences' ART27.13 shows promise in treating neuropathic pain in cancer patients, particularly those experiencing weight loss due to cancer. Nonclinical studies demonstrate its ability to reduce pain-related behaviors and improve body weight and activity levels. Interim results from the CAReS Phase 2 trial highlight its potential broader utility in cancer supportive care, addressing both anorexia cachexia syndrome and chemotherapy-induc...
07-13 13:02
